Sumatriptan succinate and Infusion site erythema - a phase IV clinical study of FDA data

Summary:

Infusion site erythema is reported as a side effect among people who take Sumatriptan succinate (sumatriptan succinate), especially for people who are female, 50-59 old, also take Vitamin D3, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Infusion site erythema when taking Sumatriptan succinate. It is created by eHealthMe based on reports of 9,380 people who have side effects when taking Sumatriptan succinate from the FDA, and is updated regularly.

What is Sumatriptan succinate?

Sumatriptan succinate has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 9,731 Sumatriptan succinate users. Check the latest studies of Sumatriptan succinate.

What is Infusion site erythema?

Infusion site erythema (reddening of the skin at infusion site) is found to be associated with 649 drugs and 383 conditions by eHealthMe. Check the latest studies of Infusion site erythema.

On Jul, 11, 2026

9,380 people reported to have side effects when taking Sumatriptan succinate.
Among them, 13 people (0.14%) have Infusion site erythema.

Could Sumatriptan succinate cause Infusion site erythema?

Among these 13 people:

What is the gender of people who have Infusion site erythema when taking Sumatriptan succinate? *

female: 100 %
male: 0.0 %

What is the age of people who have Infusion site erythema when taking Sumatriptan succinate? *

What are other drugs people take besides Sumatriptan succinate? *

Vitamin D3: 7 people, 53.85%
Montelukast Sodium: 6 people, 46.15%
Epinephrine: 6 people, 46.15%
Diphenhydramine Hydrochloride: 5 people, 38.46%
Pantoprazole Sodium: 5 people, 38.46%
Proair Hfa: 5 people, 38.46%
Aspirin: 5 people, 38.46%
Sodium Chloride: 5 people, 38.46%
Famotidine: 5 people, 38.46%
Magnesium: 4 people, 30.77%

What are other side effects people have besides Infusion site erythema? *

Nausea (feeling of having an urge to vomit): 5 people, 38.46%
Infusion Site Pain: 5 people, 38.46%
Infusion Site Swelling: 5 people, 38.46%
Fatigue (feeling of tiredness): 4 people, 30.77%
Headache (pain in head): 4 people, 30.77%
Infusion Site Bruising: 4 people, 30.77%
Lower Respiratory Tract Infection: 3 people, 23.08%
Oedema Peripheral (superficial swelling): 3 people, 23.08%
Chest Pain: 3 people, 23.08%
Dizziness: 3 people, 23.08%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 5 people, 38.46%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 23.08%
Rhinitis (a medical term for irritation and inflammation of the mucous membrane inside the nose): 2 people, 15.38%
Immune System Disorder: 2 people, 15.38%
Hypergammaglobulinaemia (elevated levels of gamma globulin): 2 people, 15.38%
Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 1 person, 7.69%
Lambert-Eaton Syndrome (this means your immune system mistakenly targets healthy cells and tissues in the body): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Sumatriptan succinate and have Infusion site erythema?

- Check whether Infusion site erythema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sumatriptan succinate:

Sumatriptan succinate (9,731 reports)

Browse all side effects of Sumatriptan succinate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site erythema:

Infusion site erythema (649 drugs)

Browse all the conditions that are associated with Infusion site erythema:

Infusion site erythema (383 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sumatriptan succinate (the active ingredients of Sumatriptan succinate) and Sumatriptan succinate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.